clinical trials

News

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Readout for AZ's hypoparathyroidism drug raises questions

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

News

Novo, Lilly trade oral GLP-1 data readouts at ECO

Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.

News

e-Lung software in the clinical setting, by Brainomix

Boehringer, Brainomix plan new trial of lung fibrosis AI

Boehringer and Brainomix are planning a prospective trial of an AI to diagnose pulmonary fibrosis, after positive results in an observational study.

News

Novo says high-dose Wegovy can cause 28% weight loss

Novo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

AZ cues up broader use of Imfinzi in bladder cancer

Readout for AZ's hypoparathyroidism drug raises questions

Novo, Lilly trade oral GLP-1 data readouts at ECO

Boehringer, Brainomix plan new trial of lung fibrosis AI

Novo says high-dose Wegovy can cause 28% weight loss

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks